Cellectar Biosciences, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

STOCKHOLDERS' EQUITY (Tables)

STOCKHOLDERS' EQUITY (Tables)

12 Months Ended

Dec. 31, 2016

Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]

The following table summarizes information with regard to outstanding warrants to purchase common stock as of December 31, 2016 (see Note 17).

	Number of Shares
	Issuable Upon
	Exercise of
	Outstanding		Exercise
Offering	Warrants		Price			Expiration Date

November 2016 Public Offering Series C		6,133,356	$	1.50		November 29, 2021
April 2016 Underwritten Registered Series A		3,626,942	$	3.04		April 20, 2021
October 2015 Incremental Series A		300,006	$	2.13		October 20, 2021
October 2015 Private Placement Series A		86,365	$	2.13		April 1, 2021
October 2015 Offering – Placement Agent		3,750	$	28.30		October 1, 2020
August 2014 Public Offering ⁽¹⁾		504,019	$	46.80		August 20, 2019
February 2013 Public Offering ⁽¹⁾		38,750	$	1.50	⁽²⁾	February 20, 2018
February 2013 Public Offering – Placement Agents		3,854	$	125.00		February 4, 2018
November 2012 Private Placement		5,000	$	250.00		November 2, 2017
June 2012 Public Offering		14,910	$	250.00		June 13, 2017
Total		10,716,952

(1)

These warrants have a certain type of cash settlement feature or their exercise prices for which the warrant may be exercised are subject to adjustment for “down-rounds” and the warrants have been accounted for as derivative instruments as described in Note 3, with the exception of 9,704 warrants issued in August 2014.

(2)

Due to the issuance of common stock at $1.50 per share as part of the November 2016 Underwritten Offering, the remaining outstanding warrants issued as part of the February 2013 Public Offering were adjusted to reflect the revised exercise price of $1.50 each.

Reserved For Future Issuance Upon Exercise Of Stock Options And Warrants Or Conversion Of Debt Text Block [Table Text Block]

The following shares were reserved for future issuance upon exercise of stock options, preferred stock conversions and warrants:

	December 31,
	2016		2015

Warrants		10,716,952		861,314
Preferred stock		1,133,339		—
Stock options		471,433		70,916
Total number of shares reserved for future issuance		12,321,724		932,230

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details